Bicycle Therapeutics plc (BCYC)
Bicycle Therapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Bicycle Therapeutics plc (BCYC) is a Biotechnology company based in GB with a market capitalization of $288.7M. Revenue grew 105.8% year-over-year and free cash flow was negative at -$252M. This page tracks BCYC's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
GB · 305 employees · IPO May 23, 2019
Valuation
Valuation & price
$4.57as of May 26, 2026· -48.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.47
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$288.7M
Market cap
105.8%
Revenue growth (YoY)
100.0%
Gross margin
-$252M
Free cash flow (USD)
-$610.6M
Net debt
Net cash position
19.0%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
4
Insider sells · 90 days
Earnings
Last report: 10-Q filed Apr 30, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 7, 2026Filing
Insider Sell $8KHannay Michael Charles Ferguson · CHIEF PROD & SUPPLY CHAIN OFF · $7.5K
- Insider sellJul 7, 2026Filing
Insider Sell $33KLee Kevin · Director, CHIEF EXECUTIVE OFFICER · $32.7K
- Insider sellJul 7, 2026Filing
Insider Sell $10KSkynner Michael · CHIEF SCIENTIFIC OFFICER · $10.2K
- Insider sellJul 7, 2026Filing
Insider Sell $6K · 10b5-1 PlanPerry Jennifer Scott · Chief Operating Officer · $6.1K
- 8-K eventJun 18, 2026Filing
Annual General Meeting Results
- 8-K eventMay 21, 2026Filing
Clinical Data Presentation
- 8-K eventApr 30, 2026Filing
First Quarter 2026 Results
- Quarterly reportApr 30, 2026Filing
10-Q Filed
- 8-K eventApr 20, 2026Filing
Program Update
Questions
Frequently asked questions
What is Bicycle Therapeutics plc's market cap?
Bicycle Therapeutics plc (BCYC) has a market capitalization of $288.7M.
What is BCYC's P/E ratio?
A meaningful P/E ratio is not available for BCYC — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is BCYC's price-to-book (P/B) ratio?
BCYC trades at 0.47 times book value per share.
Are insiders buying BCYC stock?
SEC Form 4 filings show no open-market insider buys at Bicycle Therapeutics plc in the last 90 days (4 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.